Bcg İntraVesical 120 Mcg

Bacillus Calmette-Guerin treatment of primary or simultaneous carcinoma at the site of the bladder and high-grade and / or recurrent superficial papillary transition cell carcinoma (Stage Ta (grade 2 or 3) or T1 (grade 1, 2 or 3) after transurethral resection) .

Category:

Description

Bcg İntraVesical 120 Mcg

1. Clinical information
1.1 Therapeutic indications

Bacillus Calmette-Guerin treatment of primary or simultaneous carcinoma at the site of the bladder and high-grade and / or recurrent superficial papillary transition cell carcinoma (Stage Ta (grade 2 or 3) or T1 (grade 1, 2 or 3) after transurethral resection) .

Bacillus Calmette-Guerin is recommended only for stage Ta grade 1 papillary tumors when it is decided that there is a high risk of tumor recurrence.

 

1.2 Posology and method of administration

Adults and the elderly
The contents of a reconstituted and diluted vial of Bacillus Calmette-Guerin are dropped into the bladder as indicated.
Induction therapy
Weekly vaccination with Bacillus Calmette-Guerin for the first 6 weeks.
When using superficial urothelial cell carcinoma of the bladder as an adjuvant therapy after TUR (see “Therapeutic indications”), Bacillus Calmette-Guerin treatment should be started 10 to 15 days after TUR is performed. Treatment should not be started until mucosal lesions heal after TUR heals. Treatment should also be delayed in case of gross hematuria or major bladder irritability.

Maintenance therapy

Maintenance therapy consists of weekly vaccination with Bacillus Calmette-Guerin for 3 consecutive weeks at 3, 6 and 12 months after the start of treatment. The need for maintenance therapy every 6 months after the first year of treatment should be assessed on the basis of tumor classification and clinical response.

Pediatric population
No data

Method of Application
Intravesical vaccination

Insert a catheter into the bladder through the urethra and empty the bladder completely. Connect the 50 ml syringe containing the prepared Bacillus Calmette-Guerin suspension to the catheter and inoculate the suspension into the bladder. If there is no closed system transfer device, 50 ml of Bacillus Calmette-Guerin suspension is delivered to the bladder by gravity flow. Remove the catheter after instillation. The dropped Bacillus Calmette-Guerin suspension should remain in the bladder for 2 hours. During this time, it should be noted that the grafted Bacillus Calmette-Guerin suspension has sufficient contact with the entire mucosal surface of the bladder. Therefore, the patient should not be immobilized or, if there is a patient who has stepped on the bed, should be turned from the back to his stomach or vice versa every 15 minutes. Two hours later,
Urine should be canceled in a sitting position for 6 hours after treatment and two glasses of household bleach should be added to the toilet before washing. Bleach and urine should be left in the toilet for 15 minutes before washing.
NOTE: The patient should not take any fluids starting 4 hours before instillation until the bladder is allowed to empty (eg 2 hours after instillation).

Additional information

FARMASÖTİK FORM

Vaccine (İnjection)

ETKİN MADDE

Bacillus Calmette-Guerin(BCG), Pasteur Strain 1173P2

ATC KODU

L03AX03

ATC ADI

BCG Vaccine

REÇETE TÜRÜ

Normal

TİTCK YAZILI ONAYI OLMADAN İTHAL EDİLEMEYECEK İLAÇLAR

SADECE TOPLU TEMİNİNE İZİN VERİLEN İLAÇLAR

ACİL DURUMLARDA KULLANIMI İÇİN TİTCK TARAFINDAN HASTANELERE TOPLU TEMİN İZNİ VERİLEN İLAÇLAR

ICD10 KODU

C67

ICD10 ADI

Malign Mesane Neoplazmı

KULLANIM ŞARTLARI

MESANE KANSERİ TANISINDA: A) BAŞLANGIÇ TEDAVİSİ: • AMELİYAT VEYA TUR(TRANSURETRAL REZEKSİYON) DAN EN AZ 15 GÜN SONRA BAŞLAMAK VE EN AZ 7 (YEDİ) GÜN ARAYLA 1 (BİR) DOZ* UYGULAMAK KOŞULU İLE TOPLAMDA 6 UYGULAMADAN OLUŞUR. B) İDAME TEDAVİSİ: • BAŞLANGIÇ TEDAVİSİNİ ALMIŞ HASTALARDA AMELİYAT VEYA TUR(TRANSURETRAL REZEKSİYON) TARİHİNDEN SONRAKİ 3. (ÜÇÜNCÜ), 6. (ALTINCI), 12. (ONİKİNCİ), 18.(ONSEKİZİNCİ), 24.(YİRMİDÖRDÜNCÜ), 30. (OTUZUNCU) VE 36. (OTUZALTINCI) AYLARINDA UYGULANIR. BU KAPSAMDA UYGULANACAK AYLIK TEDAVİLERDE HER AY İÇİN EN AZ 7 (YEDİ) GÜN ARAYLA UYGULAMAK KOŞULU İLE 3’ER DOZLUK* UYGULAMALARDAN OLUŞUR. C) DAHA ÖNCE İLAÇ(BCG) TEDAVİSİ ALAN VE HERHANGİ BİR ZAMANDA HASTALIĞI NÜKS EDEN HASTALARDA TEKRAR AMELİYAT OLUP OLMADIĞINA BAKILMAKSIZIN (A) MADDESİNDE BELİRTİLEN BAŞLANGIÇ TEDAVİSİ, SONRASINDA İSE (B) MADDESİNDE BELİRTİLEN İDAME TEDAVİSİ UYGULANABİLİR. * HAFTALIK TEDAVİDEKİ 1 (BİR) DOZ İÇİN ESAS ALINACAK FLAKON SAYISI;İLGİLİ İLACIN KÜB'ÜNDE BELİRTİLEN POZOLOJİ BÖLÜMÜNDE YER ALAN BİLGİLERE GÖRE HASTANIN HEKİMİ TARAFINDAN BELİRLENİR.

AÇIKLAMA

**SGK Bünyesindeki İbn-I Sina Sağlık Sosyal Güvenlik Merkezi Tarafından Barkod Talebinde Bulunulmuş Olup, Talep Uygun Bulunmuştur. **11.11.2019 Tarihinden İtibaren Geçerli Olmak Üzere Kullanım Şartlarında Değişiklik Yapılmıştır.

LİSTEYE EKLENME TARİHİ

2.04.2018

Reviews

There are no reviews yet.

Be the first to review “Bcg İntraVesical 120 Mcg”

Your email address will not be published. Required fields are marked *

Post comment